Annexon, Inc. (ANNX)

Market Cap	1.02B +381.6%
Revenue (ttm)	n/a
Net Income	-208.55M
EPS	-1.34
Shares Out	160.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,795,973
Open	6.27
Previous Close	6.35
Day's Range	6.10 - 6.39
52-Week Range	1.40 - 7.18
Beta	1.15
Analysts	Strong Buy
Price Target	16.50 (+159.64%)
Earnings Date	May 11, 2026

About ANNX

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: ANNX
• Website: https://www.annexonbio.com

Analyst Summary

According to 6 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 159.64% from the latest price.

Price Target

$16.5

(159.64% upside)

Analyst Consensus: Strong Buy